Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Innoviva Inc    INVA

INNOVIVA INC (INVA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
14.7(c) 14.62(c) 14.96(c) 15.4(c) 15.39(c) Last
917 386 770 331 828 025 716 835 487 496 Volume
-0.81% -0.54% +2.33% +2.94% -0.06% Change
More quotes
Financials (USD)
Sales 2018 266 M
EBIT 2018 243 M
Net income 2018 217 M
Debt 2018 241 M
Yield 2018 -
Sales 2019 274 M
EBIT 2019 258 M
Net income 2019 271 M
Debt 2019 41,0 M
Yield 2019 -
P/E ratio 2018 8,06
P/E ratio 2019 6,44
EV / Sales2018 6,50x
EV / Sales2019 5,56x
Capitalization 1 484 M
More Financials
Company
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals.Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone... 
Sector
Pharmaceuticals
Calendar
02/07Earnings Release
More about the company
Surperformance© ratings of Innoviva Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INNOVIVA INC
10/04INNOVIVA, INC. : Change in Directors or Principal Officers, Financial Statements..
AQ
10/01INNOVIVA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/26INNOVIVA : Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expa..
AQ
09/25GLAXOSMITHKLINE : Trelegy Ellipta receives positive CHMP opinion supporting expa..
AQ
09/21GlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
DJ
09/21INNOVIVA : Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded CO..
BU
09/11INNOVIVA, INC. : Change in Directors or Principal Officers, Financial Statements..
AQ
08/08INNOVIVA, INC. : Change in Directors or Principal Officers, Financial Statements..
AQ
08/07INNOVIVA : Theravance Biopharma, Inc. Reports Second Quarter 2018 Financial Resu..
AQ
08/02INNOVIVA, INC. : Other Events (form 8-K)
AQ
More news
Sector news : Pharmaceuticals - NEC
12:31aCorona maker's CEO Rob Sands to step down, insider to replace him
RE
10/17ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Rosmantu..
DJ
10/17Health Care Up On Stronger Earnings -- Health Care Roundup
DJ
10/17PFIZER : Looks to Reduce Headcount by 2%--Reports
DJ
10/17PFIZER : to cut around 2 percent of jobs through early next year
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/04$THRX New Form 8-K for Innoviva, Inc. From our Stock News Alerts App 
10/02$THRX New Form 8-K for Innoviva, Inc. From our Stock News Alerts App 
10/01Innoviva $INVA Raised to “Buy” at BidaskClub  
09/21$INVA: Innoviva: Trelegy Ellipta receives positive CHMP opinion supporting ex..
2
09/21$GSK: GlaxoSmithKline and Innoviva (INVA) announce Trelegy Ellipta receives p.. 
More tweets
Qtime:27
News from SeekingAlpha
09/21European advisory group backs expanded use for Glaxo's Trelegy Ellipta 
09/19The Magic Formula Needs An Upgrade 
08/01Forensic Stock Selections For August - First Year Portfolio +96.80% 
07/26Innoviva misses by $0.06, misses on revenue 
06/16Forensic Value Algorithm Stock Selections - June 
Chart INNOVIVA INC
Duration : Period :
Innoviva Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNOVIVA INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 15,0 $
Spread / Average Target -2,6%
EPS Revisions
Managers
NameTitle
Geoffrey L. Hulme Chief Executive Officer
Odysseas Demosthenes Kostas Chairman
Catherine J. Friedman Independent Director
Paul Pepe Independent Director
Patrick G. LePore Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
INNOVIVA INC5.43%1 484
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661